TTM
$43.91B
YoY change
+5.2%
5Y CAGR
+8.1%
Peak year (2022)
$62.09B
Cumulative gross profit
$1.09T
Gross Profit history chart for Pfizer (PFE) from 1985 to 2025
Latest: $44.01B
Gross Profit growth chart for Pfizer (PFE) from 1985 to 2025
Latest: +5.2%
Gross Profit history table for Pfizer (PFE) from 1985 to 2025
| 2025 | $44.01B | +5.2% | +$2.17B | ||
| 2024 | $41.85B | +37.9% | +$11.51B | ||
| 2023 | $30.34B | -51.1% | −$31.75B | ||
| 2022 | $62.09B | +32.5% | +$15.21B | ||
| 2021 | $46.88B | +56.9% | +$17.00B | ||
| 2020 | $29.88B | +4.7% | +$1.33B | ||
| 2019 | $28.55B | -24.2% | −$9.09B | ||
| 2018 | $37.64B | +2.4% | +$870.00M | ||
| 2017 | $36.77B | -0.3% | −$101.00M | ||
| 2016 | $36.87B | +3.3% | +$1.18B | ||
| 2015 | $35.69B | -1.7% | −$601.00M | ||
| 2014 | $36.30B | -3.5% | −$1.33B | ||
| 2013 | $37.63B | -6.0% | −$2.38B | ||
| 2012 | $40.02B | -8.8% | −$3.85B | ||
| 2011 | $43.87B | -5.3% | −$2.47B | ||
| 2010 | $46.34B | +20.6% | +$7.92B | ||
| 2009 | $38.42B | +0.4% | +$158.00M | ||
| 2008 | $38.26B | +4.2% | +$1.56B | ||
| 2007 | $36.70B | -3.1% | −$1.16B | ||
| 2006 | $37.86B | +2.6% | +$964.00M | ||
| 2005 | $36.90B | -11.3% | −$4.71B | ||
| 2004 | $41.61B | +17.7% | +$6.25B | ||
| 2003 | $35.36B | +24.8% | +$7.03B | ||
| 2002 | $28.33B | +4.1% | +$1.10B | ||
| 2001 | $27.23B | +6.7% | +$1.71B | ||
| 2000 | $25.52B | +79.5% | +$11.30B | ||
| 1999 | $14.22B | +19.1% | +$2.28B | ||
| 1998 | $11.94B | +11.2% | +$1.21B | ||
| 1997 | $10.73B | +12.3% | +$1.17B | ||
| 1996 | $9.56B | +16.1% | +$1.33B | ||
| 1995 | $8.23B | +23.7% | +$1.58B | ||
| 1994 | $6.65B | +11.6% | +$690.80M | ||
| 1993 | $5.96B | +9.0% | +$494.10M | ||
| 1992 | $5.47B | +9.5% | +$476.30M | ||
| 1991 | $4.99B | +14.2% | +$622.10M | ||
| 1990 | $4.37B | +14.5% | +$555.10M | ||
| 1989 | $3.82B | +7.2% | +$256.50M | ||
| 1988 | $3.56B | +11.8% | +$374.90M | ||
| 1987 | $3.18B | +9.7% | +$282.20M | ||
| 1986 | $2.90B | +11.3% | +$294.40M | ||
| 1985 | $2.61B | — | — |
- 2025$44.01B+5.2%
- 2024$41.85B+37.9%
- 2023$30.34B-51.1%
- 2022$62.09B+32.5%
- 2021$46.88B+56.9%
- 2020$29.88B+4.7%
- 2019$28.55B-24.2%
- 2018$37.64B+2.4%
- 2017$36.77B-0.3%
- 2016$36.87B+3.3%
- 2015$35.69B-1.7%
- 2014$36.30B-3.5%
- 2013$37.63B-6.0%
- 2012$40.02B-8.8%
- 2011$43.87B-5.3%
- 2010$46.34B+20.6%
- 2009$38.42B+0.4%
- 2008$38.26B+4.2%
- 2007$36.70B-3.1%
- 2006$37.86B+2.6%
- 2005$36.90B-11.3%
- 2004$41.61B+17.7%
- 2003$35.36B+24.8%
- 2002$28.33B+4.1%
- 2001$27.23B+6.7%
- 2000$25.52B+79.5%
- 1999$14.22B+19.1%
- 1998$11.94B+11.2%
- 1997$10.73B+12.3%
- 1996$9.56B+16.1%
- 1995$8.23B+23.7%
- 1994$6.65B+11.6%
- 1993$5.96B+9.0%
- 1992$5.47B+9.5%
- 1991$4.99B+14.2%
- 1990$4.37B+14.5%
- 1989$3.82B+7.2%
- 1988$3.56B+11.8%
- 1987$3.18B+9.7%
- 1986$2.90B+11.3%
- 1985$2.61B—
Gross Profit values are taken from Pfizer's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at Pfizer (PFE)
According to Pfizer's latest reported financial statements, the company's current gross profit (TTM) is $43.91B. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Pfizer (PFE) gross profit totalled $44.01B – grew 5.2% year-over-year.
Through 2020–2025 (5 years), Pfizer gross profit delivered a +8.1% annualised rate; sustaining 2 straight years of year-over-year growth.
Between 2022 and 2025, Pfizer gross profit declined 29.1%, falling from $62.09B to $44.01B.
Across the available history, gross profit reached its high of $62.09B in 2022 and its low of $2.61B in 1985.
Pfizer Gross Profit by Year
Pfizer Gross Profit 2025: $44.01B
Pfizer posted gross profit of $44.01B in 2025, grew 5.2% from 2024.
Pfizer Gross Profit 2024: $41.85B
In 2024, Pfizer reported gross profit of $41.85B, surged 37.9% from 2023.
Pfizer Gross Profit 2023: $30.34B
Pfizer gross profit in 2023 was $30.34B, plunged 51.1% below 2022.
Pfizer Gross Profit 2022: $62.09B
2022's gross profit for Pfizer came in at $62.09B, surged 32.5% from 2021. This figure represents the highest annual value in the available history.
Pfizer Gross Profit 2021: $46.88B
Pfizer gross profit in 2021 was $46.88B.
See more financial history for Pfizer (PFE).
Sector peers by Gross Profit
Healthcare peers of Pfizer (PFE), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation